+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma



Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma



European Journal of Nuclear Medicine and Molecular Imaging 40(4): 524-531



The objective of this article is to present a new method for the diagnosis of insulinoma with the use of [Lys(40)(Ahx-HYNIC-(99m)Tc/EDDA)NH2]-exendin-4. Studies were performed in 11 patients with negative results of all available non-isotopic diagnostic methods (8 with symptoms of insulinoma, 2 with malignant insulinoma and 1 with nesidioblastosis). In all patients glucagon-like peptide-1 (GLP-1) receptor imaging (whole-body and single photon emission computed tomography/CT examinations) after the injection of 740 MBq of the tracer was performed. Both sensitivity and specificity of GLP-1 receptor imaging were assessed to be 100 % in patients with benign insulinoma. In all eight cases with suspicion of insulinoma a focal uptake in the pancreas was found. In six patients surgical excision of the tumour was performed (type G1 tumours were confirmed histopathologically). In one patient surgical treatment is planned. One patient was disqualified from surgery. In one case with malignant insulinoma pathological accumulation of the tracer was found only in the region of local recurrence. The GLP-1 study was negative in the other malignant insulinoma patient. In one case with suspicion of nesidioblastosis, a focal accumulation of the tracer was observed and histopathology revealed coexistence of insulinoma and nesidioblastosis. [Lys(40)(Ahx-HYNIC-(99m)Tc/EDDA)NH2]-exendin-4 seems to be a promising diagnostic tool in the localization of small insulinoma tumours, but requires verification in a larger series of patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053423091

Download citation: RISBibTeXText

PMID: 23224740

DOI: 10.1007/s00259-012-2299-1


Related references

Glucagon-like peptide-1 receptor imaging with Lys40Ahx-HYNIC-99mTc/EDDANH2-exendin-4 for the detection of insulinoma. 2013

A freeze-dried kit formulation for the preparation of Lys(27)(99mTc-EDDA/HYNIC)-Exendin(9-39)/99mTc-EDDA/HYNIC-Tyr3-Octreotide to detect benign and malignant insulinomas. Nuclear Medicine and Biology 42(12): 911-916, 2015

Glucagon-Like Peptide-1 Receptor Imaging with [Lys (40) (Ahx-HYNIC- (99 m) Tc/EDDA)NH 2 ]-Exendin-4 for the Diagnosis of Recurrence or Dissemination of Medullary Thyroid Cancer: A Preliminary Report. International Journal of Endocrinology 2013: 384508-384508, 2013

Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clinical Cancer Research 13(12): 3696-3705, 2007

Glucagon-Like Peptide-1 Receptor Imaging with Lys40Ahx-HYNIC-99mTc/EDDANH2-Exendin-4 for the Diagnosis of Recurrence or Dissemination of Medullary Thyroid Cancer A Preliminary Report. International Journal of Endocrinology 2013: 1-6, 2013

Preparation and evaluation of 99mTc-EDDA/HYNIC-[Lys 3]-bombesin for imaging gastrin-releasing peptide receptor-positive tumours. Nuclear Medicine Communications 27(4): 371-376, 2006

Preparation via coligand exchange and characterization of (99mTc-EDDA-HYNIC-D-Phe1,Tyr3)Octreotide (99mTc-EDDA/HYNIC-TOC). Journal of Labelled Compounds and Radiopharmaceuticals 46(4): 307-318, 2003

Two peptide receptor ligands (99m)Tc-EDDA/HYNIC-Tyr(3)-octreotide and (99m)Tc-EDDA/HYNIC-(D)Glu-octagastrin for scintigraphy of medullary thyroid carcinoma. Cancer BioTherapy and Radiopharmaceuticals 22(5): 613-628, 2007

Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. Journal of Nuclear Medicine 47(12): 2025-2033, 2006

Insulinoma imaging with glucagon-like peptide-1 receptor targeting probe (18)F-FBEM-Cys (39)-exendin-4. Journal of Cancer Research and Clinical Oncology 140(9): 1479-1488, 2014

Synthesis, development and preclinical comparison of two new peptide based freeze-dried kit formulation Tc-99m-EDDA-Tricine-HYNIC-TOC and Tc-99m-EDDA-Tricine-HYNIC-TATE for somatostatin receptor positive tumor scintigraphy. Daru 14(4): 183-189, 2006

Targeted imaging of gastrin-releasing peptide receptors with 99mTc-EDDA/HYNIC-[Lys3]-bombesin: biokinetics and dosimetry in women. Nuclear Medicine Communications 29(8): 741-747, 2008

99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. European Journal of Nuclear Medicine 27(9): 1318-1325, 2000

99mTc-EDDA-HYNIC-Tyr3-octreotide for detection of somatostatin receptor positive tumors and first experience in patients. Journal of Nuclear Medicine 41(5 Suppl ): 149P-150P, 2000

Superior Diagnostic Performance of the GLP-1 Receptor Agonist [Lys 40 (AhxHYNIC-[ 99m Tc]/EDDA)NH 2 ]-Exendin-4 over Conventional Imaging Modalities for Localization of Insulinoma. Molecular Imaging and Biology 2019:, 2019